. Author manuscript; available in PMC: 2013 Nov 1.

Published in final edited form as: Clin Lung Cancer. 2012 Apr 17;13(6):448–457. doi: 10.1016/j.cllc.2012.03.002

Table 3b. Association between patient characteristics and survival in Stage III NSCLC.

	Univariate HR (95% CI)	Univariate P-Value	Multivariate HR (95% CI)	Multivariate P-Value
Age
< 65	Reference	0.02	Reference	0.38
≥ 65	1.42 (1.04-1.93)	0.02	1.21 (0.79-1.84)	0.38
Gender
Male	Reference	0.01	Reference	0.13
Female	0.68 (0.50-0.93)	0.01	0.78 (0.56-1.08)	0.13
Race
White, non-Hispanic	Reference	0.13	Reference	0.46
Other	1.27 (0.93-1.73)	0.13	1.14 (0.81-1.59)	0.46
Insurance
Private	Reference	0.15	Reference	0.78
Medicare	1.41 (0.95-2.10)		1.08 (0.66-1.78)
Indigent	1.06 (0.71-1.57)		0.92 (0.61-1.39)
Histology
Adenocarcinoma	Reference	0.13	Reference	0.26
Squamous Cell	1.07 (0.76-1.50)		0.94 (0.65-1.35)
Other ^*	0.69 (0.45-1.06)		0.70 (0.45-1.08)
Treatment ^#
“Standard”	Reference	<0.001	Reference	<0.001
Other	3.09 (2.15-4.44)	<0.001	2.81 (1.91-4.14)	<0.001

Includes patients with large cell, adenosquamous or unspecified

For treatment, standard=surgery or definitive thoracic radiation. Other =no surgery or definitive thoracic radiation